Drug intelligence / Profile preview

BX001

Development stage: Unknown
Lead developer: BiomX, Inc.
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

BX001 is a clinical-stage, topical phage therapy developed by BiomX for the treatment of acne vulgaris. It consists of a cocktail of naturally occurring bacteriophages designed to specifically target and eliminate Cutibacterium acnes (C. acnes), the bacteria implicated in acne, without harming the beneficial bacteria on the skin. In a Phase 1 study, BX001 was shown to be safe, well-tolerated, and demonstrated a statistically significant reduction in C. acnes levels on the skin. However, a subsequent Phase 2 cosmetic clinical study, while confirming safety, did not show a meaningful difference in efficacy compared to the vehicle. The company planned to evaluate the data before determining the next steps for the program.

Beyond the preview

Go deeper on BX001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BX001.

Explore the full profile